Introduction
Mental retardation (MR) can be defined as a failure to develop cognitive abilities and achieve a level of intelligence that would be appropriate for the age group. In most cases MR causes a deficit in the`adaptive behaviour'. A percentage of the general population, variably estimated between 0.5 and 2%, is reported to be functioning two standard deviations below the average (ie to have an IQ of less than 70). Genetic determinants underlie many of these conditions 1 and an excess of affected males has often been reported, 2, 3 especially in the mild-to-moderate MR range (IQ between 70 and 35). This phenomenon was eventually interpreted as being due to X-linked mutations, whose effects become more apparent in the hemizygous males who cannot compensate for deleterious mutations present on their X chromosome. Recently the prevalence of the fragile X syndrome, probably the commonest of XLMR conditions, has been re-estimated at 1/4000 males at most 6 and may represent up to 15 ± 20% of the total XLMR. Neri et al 7 prepared the first XLMR update in 1990 and tried to include all X-linked forms of mental retardation in their listing, which steadily grew to the total number of 179 entries in the previous update. 8 This XLMR update 2000 now lists 202 conditions subdivided in different nosological classes that will be illustrated in the next section.
Information sources and classification of XLMR conditions
The information sources employed to compile this listing have been many and diverse. First of all, we have regularly scanned the published literature, ie articles in scientific journals and abstracts presented at the American Society of Human Genetics, the European Society of Human Genetics and the biannual International Workshop on Fragile X and inevitable that some items may have been missed or erroneously included in this listing. Any suggestions or corrections will be gratefully accepted and it is now possible to do so in real time by contributing to the on-line XLMR database. We excluded small pedigrees with uncertain Xlinkage (eg a mother with two affected sons), but such uncertain' families may still be extremely valuable for genetic studies and could be included in a dedicated section of the on-line XLMR database. Two affected half-brothers or an affected nephew and uncle have been considered sufficient proof of X linkage.
In the nosology of XLMR, a major distinction has been made between`nonspecific' and`specific' or`syndromal' conditions. According to the HUGO Nomenclature Commit- Xp21.1-p11. 4 Generalized tonic-clonic and atonic seizures, moderate MR, normal electromyography and nerve conduction XLMR genes: update 2000 P Chiurazzi et al 74 tee (http://www.gene.ucl.ac.uk/nomenclature/), the former are indicated by the acronym MRX and the latter by the acronym MRXS, where`S' stands for`syndromal'. The terms syndromal' and`specific' are currently used interchangeably to indicate conditions that are clinically recognizable because of a specific pattern of physical, neurological, or metabolic abnormalities. 4 A dedicated survey of MRXS conditions, compiled by some of the authors of this update 2000, was recently published. 9 Sometimes MRX numbers were assigned to pedigrees that were eventually described as syndromal' and this has created some confusion. The MRX designation is actually intended for families whose only consistent clinical manifestation is X-linked MR. MRXS conditions have been somewhat arbitrarily subdivided into four classes: malformation syndromes (Table 1) , neuromuscular disorders (Table 2) , metabolic (Table 3) and dominant (Table 4) conditions. By`malformation syndrome' we mean a condition characterised by MR and multiple congenital anomalies. A`neuromuscular disorder' is one with a major involvement of the nervous system and/or muscles.`Metabolic' conditions are considered separately because their pathophysiology is known and due to the abnormal functioning of specific enzymes.`Dominant' conditions have been set apart because of their peculiar inheritance, with near absence of affected males (males die before birth, with the notable exception of one form with epilepsy and MR restricted to females) and presence of affected females. The distinction between specific and nonspecific conditions should intuitively have a molecular correlate. Actually, one can speculate that MRXS genes code for proteins with a broad range of molecular targets (eg transcriptional regulators such as XNP/ATR-X or protein kinases such as RSK2), while most of the MRX genes now cloned seem to produce proteins with more limited and specific tasks 10, 11 (eg regulating the shuttling of synaptic vesicles or modulating the establishment of synaptic contacts between neurons). This hypothesis will need further experimental support, also to explain such discrepancies as observed for the RSK2 gene mutated in the Coffin-Lowry syndrome and in the nonspecific MRX19 family, 12 or for the MeCP2 gene responsible for the Rett syndrome but also mutated in a small MRX family. 13 
Listing and maps
In Tables 1 ± 4 , which list the specific conditions, the name, the OMIM number or reference and a brief description are provided for every entry, while the gene localisation and the name of the gene are obviously indicated only where available. Table 1 contains several additions of syndromes described in the last 2 years. The presence of a second Simpson-Golabi-Behmel locus in Xp22 should be noted, 14 as it underlines the possibility of genetic heterogeneity of clinically similar/identical conditions. On the other hand, a clear example of clinical variability is represented by the ATR-X syndrome. Mutations in the XNP gene have now been found in at least four other conditions, namely JubergMarsidi (#309590), Carpenter-Waziri, 15 Holmes-Gang, 16 and a family with spastic diplegia, microcephaly and short stature. 17 An XNP mutation was also found in a family reported as Smith-Fineman-Myers, 18 though a separate entry for this latter condition is still included in Table 1 . In this case`lumping' of clinically distinguishable conditions has been possible after the gene cloning and re-screening of patients belonging to families with either a resembling phenotype or linkage to the same chromosomal interval. Until mutational screening allows more lumping, we are convinced that the wisest approach is`splitting', ie considering as different any similar but not quite identical conditions, until proven otherwise. Linkage exclusion is sometimes very useful for splitting two conditions segregating in two small families that will not reach the threshold of LOD score significance. In Table 2 , another example of lumping is offered by the spectrum of L1CAM mutations listed under HSAS (#307000), but the most extreme example of clinical variability is presently represented by the RSK2 mutations causing either the Coffin-Lowry syndrome or a nonspecific MRX. 12 It is instructive to note that the Zollino syndrome of pachygyria and MR, 19 which was present in the 1998 update, has been excluded from this update because it was found to be due to a cryptic subtelomeric translocation. Table 3 lists metabolic conditions whose genes have almost all been cloned, while Table 4 summarises the information on eight X-linked dominant disorders; genes for three of these were recently cloned. Only one of these conditions, EFMR (*300088), is not lethal in males: actually it affects exclusively females and it has been hypothesised that the responsible gene may have a homologue on the Y chromosome. A brief note should be made here to remember that a skewed X-inactivation is often observed in carrier females of these dominant mutations. One may hypothesise that cells which inactivate the normal allele die preferentially during embryogenesis or divide less than those with the normal allele on the active X chromosome. Sometimes skewage of X-inactivation is observed also in female carriers of conditions which are not lethal in males (such as ATR-X). However, in many cases there is random Xinactivation, probably because no selection occurs during early development, and female carriers may have different degrees of involvement depending on the fraction of mutant alleles on the active X chromosome. In heterozygous females two distinct cell populations will exist side by side, as nicely demonstrated, for instance, by the formation of a`double cortex' in female carriers of the XLIS (#300067) mutant gene ( Table 2 ). For reasons of space Table  5 lists only the cloned MRX genes; the complete listing of MRX conditions with their localisation can be retrieved from the on-line XLMR database. Several of these genes encode proteins involved in the control of the cytoskeleton 
The on-line XLMR database
To integrate the published XLMR update we designed a simple on-line catalogue, the XLMR database, which is now available on the Internet at http://homepages.go.com/ xlmr/home.htm. This is obviously no substitute for information derived from journals, books, expert systems and clinical experience, but it could become a useful tool if most of the fellow researchers will help to improve it and to keep it updated. Potentially, it offers a number of advantages over any published document: it can be updated as frequently as needed and there is much more space for additional information that may never be published. Presently, the on-line catalogue contains an expanded version of Tables 1 ± 6 of this update (extra columns are available and the OMIM numbers and references are hyperlinked). A colour-coded version of Figures 1 and 2 is also available and we plan to hyperlink the conditions mentioned there with the corresponding Tables. An individual record for every condition would be highly desirable, possibly with more information on the cloned genes (with a link to Locuslink of NCBI, at least). Also, thanks to the space available, the complete linkage data might be attached and Figure 2 Ideogram of the X chromosome (G-banding) with the localisation of the seven cloned MRX genes (arrows) and of the 59 mapped MRX families (bars). The extra cloned gene indicated is RSK2, which is also depicted in Figure 1 and most often mutated in the Coffin-Lowry syndrome (Table 1) .
XLMR genes: update 2000 P Chiurazzi et al 78 information on all tested loci (and not only recombinant ones) could be compared between overlapping conditions. Negative linkage data, which are not easily publishable but still very relevant and useful, may be stored. Eventually, images could be attached to the card describing each specific XLMR condition. Finally, a listing of available DNA from small families or individual cases with cytogenetic rearrangements in the various laboratories researching on XLMR may be envisaged, which would certainly boost the opportunity for collaboration. In brief, this informal Web site could become a`meeting point' for the XLMR community.
Future research
Although the primary sequence of the human genome will soon be completed, the cloning era is far from being concluded and much`sequence mining' and`traditional' cloning remains to be done to account for the 202 XLMR conditions listed in this update. Many of these may eventually prove to be due to mutations in the same gene but the present number of 33 cloned XLMR genes definitely falls short of the actual amount. Unexpectedly, mutations in already cloned genes were not found to account for mental retardation in families mapping to the same narrow intervals where these genes are located. Therefore, new strategies will have to be designed to exploit even small families and individual patients for the identification of new XLMR genes. Some recent observations are encouraging. We now appreciate the value that even small families or individual patients with cytogenetic rearrangements can have in helping to pin down the remaining genes. For example, the MRX genes IL1RAPL and TM4SF2 were identified thanks to the observation of patients with a microdeletion and an X;autosome translocation, respectively, and confirmatory mutations were found in small families that could not reach a linkage significance. DNA chip technology will hopefully allow (re)screening of large numbers of patient DNAs for mutations in several candidate genes at the same time, as well as testing the expression of these genes in informative families. Finally, the next challenge awaiting us will be the unravelling of the structure and function of the proteins encoded by the XLMR genes. This will be a daunting task belonging to the new era of`proteomics' but will surely lead us to a better understanding of the biological pathways required for the normal development of intelligence.
